OnCo
technologiesTechnologyPhase 2

Photothermal (plasmonic) nanoparticle ablation

Gold nanoshells that accumulate in a tumour and cook it when a near-infrared laser is shone on them.

AuroLase uses silica-gold nanoshells that convert near-infrared light into heat. Nanospectra ran focal prostate ablation studies with MRI/ultrasound fusion guidance (NCT02680535, completed; extension NCT04240639, status unknown) and a lung study that was terminated. Published prostate cohorts reported ablation of the treated zone with preserved urinary and sexual function, but the technology has never been compared with established focal therapy in a randomised trial.

Generic schematic · not to scale · placeholder for the devices front
Transducer arrays · 100-300 kHz alternating field · Mitosis disrupted

How it works

Nanoparticles tuned to absorb 800 nm light accumulate in tumour vasculature; laser illumination raises local temperature above the ablation threshold while surrounding tissue, lacking particles, is spared.

Strengths
  • Focal, repeatable, organ-preserving
  • No ionising radiation
  • Rapid outpatient procedure
Limitations
  • Light penetrates only a few centimetres
  • Delivery depends on leaky vasculature, which is unreliable in humans
  • No randomised efficacy data; commercial progress has stalled

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Photothermal plasmonic nanoparticle ablation" OR ABSTRACT:"Photothermal plasmonic nanoparticle ablation") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Photothermal (plasmonic) nanoparticle ablation, not a curated reading list.

Connected

7top